Communiqués Agenus Inc.

Actions

AGEN

US00847G8042

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 09/09/2026			Varia. 5j.	Varia. 1 janv.
6,860 ^USD	-7,67%		-14,14%	+118,47%

28/08	Agenus annonce la publication par des pairs des résultats matures de phase 1b pour l'association botensilimab et balstilimab dans le cancer colorectal métastatique avec microsatellites stables	CI
26/08	Agenus publie les résultats actualisés de la phase 2 de l'étude NEST sur l'association néoadjuvante botensilimab et balstilimab dans le cancer du côlon résécable	CI

Communiqués

31/08	Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism	AQ
31/08	Agenus to Participate in Upcoming September Investor Conferences	BU
28/08	Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism	BU
26/08	Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer	BU
07/08	Agenus: Q2 Earnings Snapshot	AQ
06/08	Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer	BU
28/07	Agenus to Provide Second Quarter 2026 Financial Report and Development Update	BU
27/07	GSK's Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Canada	AQ
17/07	Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026	BU
15/07	Agenus annonce un placement privé sursouscrit de 340 millions USD pour faire avancer l'essai d'enregistrement ROBBIN évaluant le néoadjuvant BOT+BAL dans le cancer du côlon MSS	BU
13/07	Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer	BU
07/07	Agenus présente à l’ESMO GI 2026 des données marquantes sur le traitement BOT+BAL, montrant un taux de survie globale à trois ans de 33 % chez les patients atteints d’un cancer colorectal métastatique réfractaire de type MSS sans métastases...	BU
06/07	Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026	BU
25/06	Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026	BU
02/06	Agenus Announces Virtual 2026 Annual Shareholders Meeting	BU
21/05	Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC	BU
21/05	Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026	BU
15/05	Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer	BU
11/05	Agenus: Q1 Earnings Snapshot	AQ
11/05	Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development	BU
04/05	Agenus to Provide First Quarter 2026 Financial Report and Corporate Update	BU
22/04	Agenus désigne BAP Pharma comme partenaire mondial exclusif pour les programmes d’accès à la combinaison BOT+BAL	BU
21/04	Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026	BU
21/04	Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs	BU
17/04	Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer	BU